

# Index

Note: Page numbers followed by *f* indicate figures, *t* indicate tables, and *b* indicate boxes.

## A

ABO blood group, 29  
Absolute abundance, 69–71  
*Actinomyces odontolyticus*, 110  
Adhesion, 33–35  
Adipose tissue, 63  
*Aggregatibacter*  
    *actinomycetemcomitans*, 89  
*Akkermansia muciniphila*, 24*f*,  
    143–144  
Alzheimer's disease, 163  
Amplicon sequencing, 59–60  
Aryl hydrocarbon receptor (AhR)  
    agonists, 166–167*t*  
Atherosclerotic cardiovascular  
    disease (ACVD), 94  
Atherosclerotic plaque-associated  
    bacteria, 91–93*t*  
Autoantigens, 146–147

## B

*Bacillus anthracis*, 134*f*  
Bacteria, 119*b*  
Bacterial genomes, 111–112*f*  
Bacterial species, 120–121*f*  
Bacterial strains, 118  
*Bacteroides fragilis*, 2*f*, 35–37  
*Bacteroides thetaiotaomicron*, 24*f*  
*Bifidobacterium animalis* subsp.,  
    24*f*  
Biomarkers, 159–160  
Branched chain amino acids  
    (BCAAs), 144–146  
Bristol's stool score (BSS), 57

## C

Cancer screening, 160  
Cancer therapy, 168*f*  
Candidate phyla radiation (CPR),  
    113*f*  
Cardiometabolic diseases, 89–94  
Cardiovascular diseases, 94  
Causality, 149

Causal reasoning, 133–138  
Cell-free DNA (cfDNA), 160*b*  
Cell-free RNA (cfRNA), 160*b*  
*Christensenella minuta*, 24*f*  
Circadian rhythm, 43*b*  
Circulation, 97  
Colonoscopy, 159–160  
Colorectal cancer, 175–176  
Commensal microbes, 84–88  
Commercial deoxyribonucleic  
    acid (DNA) tests, 202  
*Corynebacterium* spp., 10*f*  
COVID-19 pandemic, 83–84  
    epidemiology, 83  
CPR. *See* Candidate phyla  
    radiation (CPR)  
Culturomics, 110  
*Cutibacterium acnes*, 29–31

## D

Dental bacteria, 3*b*  
Deoxyribonucleic acid (DNA)  
    extraction, 57–58  
        metagenomic samples,  
            67–68  
    sequencing amount, 57–58  
Diabetes, 144–146  
Dietary fibers, 195–200  
Drug metabolism, 168*f*

## E

Enterotypes, 38–46  
*Escherichia coli*, 2*f*

## F

*Faecalibacterium prausnitzii*, 24*f*,  
    135–136  
Fecal microbiome, 29*b*  
Fungal taxonomy, 114*f*  
*Fusobacterium* spp., 175–176

## G

Gut microbiome, 33–38, 169–170*t*  
    circadian rhythm, 43*b*

## H

Habitats, 29–31  
*Helicobacter pylori*, 141–142  
Hematogenous spread, 86  
Higher-taxonomic resolution,  
    118–121  
Histone deacetylase 3 (HDAC3), 43

## I

Immunoglobulin A (IgA), 33–35  
Indoleamine 2,3-dioxygenase  
    1(IDO1) inhibitors,  
        164–165*t*  
Infant gut microbiota, 84  
Interkingdom interactions, 94–96

## K

Koch's postulates, 133

## L

*Lachnospiraceae*, 33–35  
*Lactobacillus crispatus*, 94  
LCT alleles, 29  
Liver diseases, 157–159  
Low biomass samples, 59–65  
Lymphatic drainage, 86

## M

Machine learning, 118–119  
Macroecology, 21  
Mendelian randomization (MR),  
    138–141, 139*b*  
Metabolomics, 97  
Metagenome, 6*b*  
Metagenome-assembled genomes  
    (MAGs), 109  
Metagenome-wide association  
    studies (MWAS), 71–73  
Metagenomics, 1–5  
    deoxyribonucleic acid, 67–68  
    disease screening, 157–161  
    personalized treatment,  
        161–163  
    *vs.* traditional microbiology, 5*f*

- Metagenomic shotgun sequencing, 67
- Methanobrevibacter*, 40
- Methanobrevibacter smithii*, 24f, 40b
- Methanogenic archaea, 40b
- Microbial cells, 5–12
- Microbial counts, 7
- Microbial diversity, 46
- Microbial genomes, 120–121f
- Microbial growth, 65–67
- Microbiology, 5f
- Microbiome, 6b
- from ancient times, 13–16
  - cancer therapies, 162–163t
  - causal evidence, 140–141t
  - diseases, 138–143, 175–177
  - diversity, 21–26, 27t
  - female reproductive tract, 11f
  - immediate and historical events, 192–200
  - interkingdom interactions, 94–96
  - omics, 97–101
  - record from birth, 189–192
  - richness, 21–26
  - species, 13
  - stability, 21–26
- Microbiota, 6b
- de novo assembly, 26–28
- Microflora, 21
- Microscopy, 1
- Mucosal lining, 26b
- Multiple effective molecules, 143–144
- MWAS. *See* Metagenome-wide association studies (MWAS)
- Mycobacterium abscessus*, 174–175
- Mycobiota, 87f
- Mycoplasma genitalium*, 124–126, 125–126f
- N**
- Newton's simplicity rule, 135b
- O**
- Occult sepsis, 86
- Ockham's razor, 135b
- Opportunistic pathogen, 133
- Oral hygiene, 142
- Oral microbiome, 31–33
- Organ-specific metabolite production, 97–98t
- Outer membrane vesicles, 147–149
- P**
- Paleogenomics, 13–16
- Pancreatic ductal adenocarcinoma (PDAC), 12f
- Path diagrams, 135–136
- Peristalsis, 35–38
- Permutational analyses of variances (PERMANOVA), 72
- Phages, 147–149
- Placenta microbiome, 62–63
- Pollution, 201
- Poly-genetic risk scores (PRS), 200–201
- Polymerase chain reaction (PCR), 84–88
- Prevotella copri*, 122f
- Probiotics, 200
- Prokaryotic traits, 15f
- R**
- Randomized controlled trials (RCTs), 139
- Rheumatoid arthritis (RA), 88–89
- prevention, 203f
- Ribosomal RNA (rRNA), 62f
- Robustness, 26–28
- Ruminococcaceae*, 33–35
- S**
- Sequencing amount, 68–69
- The Serengeti rules, 38–46
- Shotgun metagenomic data, 59t
- Single-cell sequencing, 202
- Skin microbiome, 29–31
- Sparsity, 118
- Streptococcus parasanguinis*, 139
- Supra-gingival dental calculus, 15f
- T**
- Treponema* spp., 23b
- Treponema succinifaciens*, 24f
- Trimethylamine (TMA), 40
- Trimethylamine N-oxide (TMAO), 40b
- Trophic levels, macroecology, 21
- V**
- Viral particles, 12–13
- Virus-like particles (VLPs), 12
- Vitamins, 201
- W**
- Whole-cell modeling, 124–127